SUPN · NASDAQ
Supernus Pharmaceuticals, Inc.
$40.70 +0.88 (+2.14%)
Company overview
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products include Trokendi XR, an extended-release topiramate product indicated for the treatment of epilepsy and the prophylaxis of migraine headache; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 and 17 years of age.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $2.4B
- Employees
- 674
- Headquarters
- Rockville, MD
- Website
- supernus.com
- CEO
- Jack A. Khattar
- Listed
- May 1, 2012
- P/E
- -79.59
- Dividend yield
- 0.00%
Company financials
- Revenue
- $777M
- Gross profit
- $695M
- Operating income
- -$41.7M
- EBITDA
- $43.4M
- Net income
- -$29M
- EPS
- -$0.51
- Total assets
- $1.5B
- Total debt
- $40.9M
- Gross margin
- 89.42%
- Net margin
- -3.74%
- Earnings yield
- -1.26%
No geographic segmentation.
Showing FY 2025
SUPN
1D
NASDAQ
O41.33H41.66L39.96C40.69-1.38 (-3.28%)Vol400.80K